Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 wild-type MERTK pos |
| Therapy | MRX-2843 |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 wild-type MERTK pos | acute myeloid leukemia | sensitive | MRX-2843 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MRX-2843 inhibited Mertk signaling, resulted in growth inhibition in FLT3 wild-type acute myeloid leukemia cells in culture and in cell line xenograft models, and prolonged survival in patient-derived xenograft models (PMID: 27158668). | 27158668 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27158668) | The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. | Full reference... |